Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. TARS
stocks logo

TARS

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
95.81M
+134.76%
--
--
104.02M
+116.18%
--
--
123.54M
+86.04%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Tarsus Pharmaceuticals, Inc. (TARS) for FY2025, with the revenue forecasts being adjusted by 11.85% over the past three months. During the same period, the stock price has changed by -15.92%.
Revenue Estimates for FY2025
Revise Upward
up Image
+11.85%
In Past 3 Month
Stock Price
Go Down
down Image
-15.92%
In Past 3 Month
5 Analyst Rating
up Image0
Wall Street analysts forecast TARS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is 79.00 USD with a low forecast of 72.00 USD and a high forecast of 85.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 39.930
sliders
Low
72.00
Averages
79.00
High
85.00
up Image0
Current: 39.930
sliders
Low
72.00
Averages
79.00
High
85.00
Oppenheimer
Oppenheimer
Outperform
upgrade
$72 -> $75
2025-06-02
Reason
Oppenheimer
Oppenheimer
Price Target
$72 -> $75
2025-06-02
upgrade
Outperform
Reason
Oppenheimer assumed coverage of Tarsus Pharmaceuticals with an Outperform rating with a price target of $75, up from $72. The firm notes the company reported Q1 2025 topline of $78.3M, beating consensus estimates, with volume of about 72K surpassing guidance. XDEMVY's momentum remains strong, driven by its growth initiatives. Management highlighted encouraging shifts in prescribing patterns from monthly to weekly prescribing, noting that thousands of target ECPs remain below capacity. Oppenheimer is encouraged by broad commercial, Medicare, and Medicaid coverage. With sales force expansion, coverage, DTC, and evidence generation progressing, plus a strengthened balance sheet, the firm believes XDEMVY's momentum is well-poised to grow.
H.C. Wainwright
Oren Livnat
initiated
$72
2025-05-27
Reason
H.C. Wainwright
Oren Livnat
Price Target
$72
2025-05-27
initiated
Reason
H.C. Wainwright analyst Oren Livnat assumed coverage of Tarsus Pharmaceuticals with a Buy rating and $72 price target. The firm likes the company's Xdemvy impetus in Demodex blepharitis. Xdemvy represents the first and only FDA approved therapy to treat Demodex blepharitis, the analyst tells investors in a research note.
Jefferies
Anthony Petrone
Strong Buy
Maintains
$54 → $58
2025-03-06
Reason
Jefferies
Anthony Petrone
Price Target
$54 → $58
2025-03-06
Maintains
Strong Buy
Reason
Jefferies raised the firm's price target on Tarsus Pharmaceuticals to $58 from $54 and keeps a Buy rating on the shares. The firm says it is surprised the stock is down over 20% year-to-date given the impressive Q4 and FY24 results, which outperformed expectations every quarter; its outlook for about 100% revenue growth in 2025; and the company quickly approaching cash flow breakeven. As a result, Jefferies does not think the shares in the mid-40s adequately reflect the successful Xdemvy launch plus the path to profitability, which it believes is 2025/2026.
Barclays
Balaji Prasad
Buy
Maintains
$62 → $60
2025-02-26
Reason
Barclays
Balaji Prasad
Price Target
$62 → $60
2025-02-26
Maintains
Buy
Reason
Barclays lowered the firm's price target on Tarsus Pharmaceuticals to $60 from $62 and keeps an Overweight rating on the shares following the Q4 report. The firm says Xdemvy 2025 sales growth will vary by quarter.
HC Wainwright & Co.
Oren Livnat
Strong Buy
Reiterates
$73
2025-02-26
Reason
HC Wainwright & Co.
Oren Livnat
Price Target
$73
2025-02-26
Reiterates
Strong Buy
Reason
Guggenheim
Eddie Hickman
Strong Buy
Maintains
$75 → $78
2025-02-26
Reason
Guggenheim
Eddie Hickman
Price Target
$75 → $78
2025-02-26
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tarsus Pharmaceuticals Inc (TARS.O) is -66.19, compared to its 5-year average forward P/E of -13.85. For a more detailed relative valuation and DCF analysis to assess Tarsus Pharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.85
Current PE
-66.19
Overvalued PE
4.70
Undervalued PE
-32.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.97
Current EV/EBITDA
178.58
Overvalued EV/EBITDA
39.46
Undervalued EV/EBITDA
-41.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
18.96
Current PS
3.74
Overvalued PS
32.49
Undervalued PS
5.44

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 987.14% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

TARS News & Events

Events Timeline

(ET)
2025-05-05
06:33:33
Elanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
select
2025-05-01 (ET)
2025-05-01
16:40:13
Tarsus Pharmaceuticals reports Q1 EPS (64c), consensus (63c)
select
2025-03-13 (ET)
2025-03-13
07:02:37
Tarsus Pharmaceuticals 2.809M share Spot Secondary priced at $44.50
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
06-18NASDAQ.COM
Tarsus Pharmaceuticals Becomes Oversold (TARS)
  • Tarsus Pharmaceuticals Stock Performance: Tarsus Pharmaceuticals Inc (TARS) shares have entered oversold territory with an RSI of 29.6, indicating potential buying opportunities after recent heavy selling, as the stock trades around $39.42, significantly above its 52-week low of $20.08 and below its high of $57.28.

  • Market Comparison: In contrast, the S&P 500 ETF (SPY) has a higher RSI reading of 60.8, suggesting that TARS may be experiencing a unique market condition compared to broader market trends.

Preview
2.0
06-06NASDAQ.COM
TARS Makes Bullish Cross Above Critical Moving Average
  • Stock Performance Overview: TARS's stock has a 52-week low of $20.0818 and a high of $57.28, with the last trade recorded at $44.52.

  • Author's Perspective Disclaimer: The opinions expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.

Preview
1.0
05-30Newsfilter
Tarsus to Participate in Upcoming Investor Conferences
  • Upcoming Investor Conferences: Tarsus Pharmaceuticals will participate in three investor conferences in June 2025, including the William Blair Annual Growth Stock Conference, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference, with live webcasts available on their website.

  • Company Overview: Tarsus Pharmaceuticals focuses on innovative treatments in eye care and infectious disease prevention, with FDA-approved products like XDEMVY for Demodex blepharitis and ongoing development of TP-04 and TP-05 for ocular rosacea and Lyme disease prevention, respectively.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tarsus Pharmaceuticals Inc (TARS) stock price today?

The current price of TARS is 39.93 USD — it has decreased -2.96 % in the last trading day.

arrow icon

What is Tarsus Pharmaceuticals Inc (TARS)'s business?

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

arrow icon

What is the price predicton of TARS Stock?

Wall Street analysts forecast TARS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARS is 79.00 USD with a low forecast of 72.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tarsus Pharmaceuticals Inc (TARS)'s revenue for the last quarter?

Tarsus Pharmaceuticals Inc revenue for the last quarter amounts to 78.34M USD, increased 183.68 % YoY.

arrow icon

What is Tarsus Pharmaceuticals Inc (TARS)'s earnings per share (EPS) for the last quarter?

Tarsus Pharmaceuticals Inc. EPS for the last quarter amounts to -0.64 USD, decreased -36.63 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tarsus Pharmaceuticals Inc (TARS)'s fundamentals?

The market is revising Upward the revenue expectations for Tarsus Pharmaceuticals, Inc. (TARS) for FY2025, with the revenue forecasts being adjusted by 11.85% over the past three months. During the same period, the stock price has changed by -15.92%.
arrow icon

How many employees does Tarsus Pharmaceuticals Inc (TARS). have?

Tarsus Pharmaceuticals Inc (TARS) has 323 emplpoyees as of July 08 2025.

arrow icon

What is Tarsus Pharmaceuticals Inc (TARS) market cap?

Today TARS has the market capitalization of 1.68B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free